// App-Quantinova.ai

4052 : Improvement in Clinical Benefit Parameters with Pomalidomide (POM) in Combination with Low-Dose Dexamethasone (LoDEX) in Patients with Relapsed and Refractory Multiple Myeloma (RRMM): Results From a Phase 2 Study

Researchers

Presenter

  • Rachid Baz

Principal Investigators

  • Maritza Lienlaf

  • Nizar J. Bahlis

  • Christine I. Chen

  • Kenneth C. Anderson

  • Min Chen

  • Mohamed Zaki

  • Paul G. Richardson

Medical Centers

  • Department of Malignant Hematology, H. Lee Moffitt Cancer Center & Division of Hematology, University of Calgary, Southern Alberta Cancer Research Institute, Calgary, AB, Canada

  • Division of BMT, Emory University, Winship Cancer Institute - Hematology and Medical Oncology, Atlanta, GA

  • Princess Margaret Hospital, Toronto, ON, Canada

Locations

  • United States

  • Canada

Companies

  • Celgene Corporation

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Multiple Myeloma

  • Peripheral neuropathy

Biomarkers

  • Cluster of differentiation 79A

  • Creatinine

  • Human albumin

  • Immunoglobulin G

Drug/Treatment

  • Dexamethasone

  • Dekpak 13 Day Taperpak

  • Pomalidomide

  • CC-4047

  • Aspirin

  • Albyl-E

Outcome

  • N/A

Study Design

  • open label

  • randomized

Phase

  • II

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved